Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) EBIT (2016 - 2025)

Historic EBIT for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to -$1.2 million.

  • Abvc Biopharma's EBIT fell 28648.63% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.9 million, marking a year-over-year decrease of 772.18%. This contributed to the annual value of -$4.7 million for FY2024, which is 3046.51% up from last year.
  • Latest data reveals that Abvc Biopharma reported EBIT of -$1.2 million as of Q3 2025, which was down 28648.63% from -$2.3 million recorded in Q2 2025.
  • Abvc Biopharma's 5-year EBIT high stood at -$302316.0 for Q3 2024, and its period low was -$6.4 million during Q4 2021.
  • For the 5-year period, Abvc Biopharma's EBIT averaged around -$2.2 million, with its median value being -$2.0 million (2021).
  • As far as peak fluctuations go, Abvc Biopharma's EBIT plummeted by 39640.76% in 2022, and later soared by 8597.06% in 2024.
  • Quarter analysis of 5 years shows Abvc Biopharma's EBIT stood at -$6.4 million in 2021, then surged by 51.41% to -$3.1 million in 2022, then surged by 83.66% to -$511835.0 in 2023, then crashed by 37.65% to -$704564.0 in 2024, then tumbled by 65.83% to -$1.2 million in 2025.
  • Its EBIT was -$1.2 million in Q3 2025, compared to -$2.3 million in Q2 2025 and -$693005.0 in Q1 2025.